drugset
drugset / Trial / NCT01095666

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

NCT01095666 ↗

Phase 3 Completed 1484 enrolled AstraZeneca Astra Zeneca, Bristol-Myers Squibb · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in Asian patients with Type 2 Diabetes who are not well controlled on metformin alone. The safety of this treatment will also be studied.

Timeline

Start
2010-06
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 5 mg Oral
Subject Dapagliflozin Small molecule 10 mg Oral
Background Metformin Small molecule 1500 mg Oral
Background Metformin Small molecule 3000 mg Oral
Background Pioglitazone Small molecule 15 mg Oral
Background Pioglitazone Small molecule 45 mg Oral

Indications

type 2 diabetes mellitus